Bayer shines in Frankfurt, positive test on drug for chronic kidney disease
The German giant announced that finerenone, marketed under the name Kerendia, met the primary endpoint in the phase III Find-ckd study
Le ultime da Radiocor
###Morning note: economia e finanza dai giornali
***Iran: da Usa nuovi attacchi e ripristino sanzioni dopo navi colpite a Hormuz
### Morning note: l'agenda di mercoledi' 8 luglio
(Il Sole 24 Ore Radiocor)- Bayer is shining on the Frankfurt Stock Exchange thanks to the positive outcome of tests on a drug for a kidney disease. The German giant reported that finerenone, marketed under the name Kerendia, met the primary endpoint in the phase III Find-ckd study in patients with non-diabetic chronic kidney disease, which assessed the drug's efficacy and safety.
Bayer emphasised that finerenone significantly delayed renal disease progression in patients with Mrc compared to placebo in addition to standard therapy. The Find-Ckd study, the company indicated, "is the largest Phase III trial conducted to date in non-diabetic Mrc". So far, limited treatment options are available for patients with non-diabetic Mrc and there is a high need for new treatments to delay renal disease progression and reduce cardiovascular risk, Bayer also pointed out.
Finerenone has been studied so far in more than 20,000 patients with chronic kidney disease and/or heart failure. Bayer plans to submit this data to the US Food and Drug Administration (Fda) to extend Kerendia's indication to patients with non-diabetic chronic kidney disease. As of 2021, Kerendia is already approved for certain diseases with renal and cardiovascular implications. Data from the Find-Ckd clinical study will be presented at an upcoming scientific congress.
